InvestorsHub Logo
Followers 826
Posts 119439
Boards Moderated 16
Alias Born 09/05/2002

Re: indigokid post# 15008

Wednesday, 11/18/2015 4:46:56 PM

Wednesday, November 18, 2015 4:46:56 PM

Post# of 20689

…seems like the analysts don't really understand MNTA?

Case in point: Right up until the date of FDA approval, analysts routinely asked Crag Wheeler why MNTA hadn’t run clinical trials to demonstrate the safety and efficacy of generic Copaxone as Teva did with thrice-weekly Copaxone.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”